BLAINJECTIONINJECTABLE
Approved
Jun 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
6/8 — Strong
ZIRABEV (bevacizumab-bvzr) by Pfizer is vascular endothelial growth factor-directed antibody interactions [moa]. Approved for colorectal cancer, hepatocellular carcinoma, breast cancer and 1 more indications. First approved in 2019.
ZIRABEV (bevacizumab-bvzr) is a monoclonal antibody (MAb) developed by Pfizer and approved on June 27, 2019, that targets vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis. As a biosimilar to the reference AVASTIN, it is indicated for VEGF-driven malignancies and ocular conditions where new blood vessel formation drives disease progression. The drug works by binding VEGF and preventing its interaction with endothelial growth factor receptors, thereby blocking tumor blood supply and reducing pathological neovascularization. ZIRABEV competes in the mature anti-VEGF therapeutic class alongside both reference products and other biosimilars.
$0.0BPart D
Mechanism of Action
Vascular Endothelial Growth Factor-directed Antibody Interactions
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications (4)
Worked on ZIRABEV at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.